tafamidis

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype

Conditions

Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype

Trial Timeline

Mar 8, 2023 → May 19, 2023

NCT ID

NCT05139680

About tafamidis

tafamidis is a pre-clinical stage product being developed by Pfizer for Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype. The current trial status is completed. This product is registered under clinical trial identifier NCT05139680. Target conditions include Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06393465	Pre-clinical	Active	Jun 15, 2024	Feb 20, 2026	Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
NCT06086353	Pre-clinical	Completed	Mar 25, 2024	Jun 6, 2025	Transthyretin Amyloid Cardiomyopathy
NCT05139680	Pre-clinical	Completed	Mar 8, 2023	May 19, 2023	Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
NCT05560555	Pre-clinical	Completed	Oct 24, 2022	Nov 15, 2022	Hereditary Transthyretin Amyloidosis (ATTRv)
NCT04814186	Approved	Completed	Jul 22, 2021	Oct 16, 2023	Transthyretin Amyloid Cardiomyopathy
NCT03662191	Phase 1	Completed	Sep 28, 2018	Jan 10, 2019	Healthy Volunteers
NCT03280173	Phase 1	Completed	Sep 29, 2017	Feb 23, 2018	Healthy
NCT03266705	Phase 1	Completed	Sep 20, 2017	Mar 1, 2018	Healthy
NCT02791230	Phase 3	Completed	Jun 13, 2016	Nov 2, 2023	Transthyretin (TTR) Amyloid Cardiomyopathy
NCT02746926	Phase 1	Completed	Apr 29, 2016	Jul 15, 2016	Healthy
NCT02697864	Phase 1	Completed	Apr 1, 2016	Jun 1, 2016	Healthy
NCT01435655	Phase 3	Completed	Nov 1, 2011	Feb 1, 2014	Transthyretin Familial Amyloid Polyneuropathy
NCT00935012	Phase 3	Completed	Sep 30, 2009	Nov 20, 2019	ATTR-CM
NCT00925002	Phase 3	Completed	Aug 5, 2009	Jul 8, 2020	ATTR-PN

Competing Products

20 competing products in Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype

See all competitors

Product	Company	Stage	Hype Score
KVD900	KalVista Pharmaceuticals	Phase 2	47
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 1	28
KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	72
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	18
KVD900 + Placebo to KVD900	KalVista Pharmaceuticals	Phase 1	28
Sebetralstat	KalVista Pharmaceuticals	Pre-clinical	18
Placebo + KVD900 600 mg + KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	72
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet	KalVista Pharmaceuticals	Phase 1	28
KVD900 150 mg + KVD900 300 mg + KVD900 600 mg	KalVista Pharmaceuticals	Phase 3	72
KVD824 + Placebo to KVD824	KalVista Pharmaceuticals	Phase 2	47
KVD900 600 mg + Drug: KVD900 300 mg	KalVista Pharmaceuticals	Phase 3	72
Deferasirox FCT	Novartis	Phase 2	52
Canakinumab + Placebo	Novartis	Phase 3	77
Ilaris	Novartis	Pre-clinical	23
Standard of Care for Haemophilia A	Roche	Pre-clinical	23
Emicizumab	Roche	Phase 3	77
Tafamidis	Pfizer	Pre-clinical	22
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	22
Nitisinone	Swedish Orphan Biovitrum	Phase 1	32
Nitisinone	Swedish Orphan Biovitrum	Pre-clinical	22

Other Products from Pfizer